Patients who remain on a stable maintenance dose frequently report ongoing improvements in portion control and reduced cravings
Barrett E, Fitzgerald P, Dinan TG, Cryan JF, Ross RP, Quigley EM, et al
As every patient responds differently, ongoing clinical review and an individualised approach remain essential throughout treatment
In line with evidence accrued in patients with T2D, incretin-based therapies produced a favorable effect on traditional cardiovascular risk factors, such as lipids and blood pressure, and even reduced the risk of major cardiovascular events and heart failure-related events in individuals with obesity, as recently demonstrated for the first time in the SELECT trial with semaglutide 2.4 mg once-weekly
( a ) Day 48 % change in body weight, ( b ) body weight over time, and ( c ) average daily food intake measured every 3 days